



BIOGRAPHICAL SKETCH

Name and Surname: **Ciro Francesco Ruggiero**

WORK EXPERIENCE

December 2018 – July 2020

Fellowship at Regina Elena Institute (IFO) - Rome, via ElioChianesi, 53 - 00144 Rome

Project title: "A miRNA-based signature as predictive biomarker of drug resistance in metastatic melanoma".

February 2015 - August 2015

Pharmaceutical representative at PetitPharma pharmaceutical company s.p.a.

EDUCATION

November 2015 –November 2018

PhD in Molecular and Translational Oncology and Innovative Medical-Surgical Technologies (XXXI cycle) - "Magna Graecia" University of Catanzaro - 16/04/2019 *Dissertation: "MICRORNA DEREGLATION ORCHESTRATES THE DEVELOPMENT OF RESISTANCE TO TARGETED THERAPIES IN MELANOMA"*

October 2014

Master's Degree in Biology (LM-6) - University of Naples 'Federico II' Rating: 106/110

December 2011

Bachelor's Degree in Biological Sciences - University of Campania 'Luigi Vanvitelli' Rating: 109/110

RESEARCH EXPERIENCE

Study of drug-resistance molecular mechanisms in melanoma. In particular I investigated how the deregulation of the small non-coding RNAs (microRNAs) can be a key event in triggering the development of resistance to current target therapies in metastatic melanoma.

TECHNICAL SKILLS AND COMPETENCES

Growth of melanoma cell cultures; transient transfection of miRNAs and plasmids, apoptosis test. Colorimetric proliferation assays. ELISA assays. Immunofluorescence to evaluate cell proliferation. Extraction of RNA and proteins from cellular lysates; Western Blotting and Real Time PCR tests. Bacterial cultures, cloning. Isolation and evaluation of miRNAs from cell cultures, formalin-fixed, paraffin-embedded (FFPE), plasma samples and extracellular vesicles (EVs). Isolation of EVs from cell culture media and human plasma samples. Flow cytometry.

-**English language (Test of interactive English CEFR Level: B2)** - GATEHOUSE AWARDS LTD - Date certification: March 2018 – License 2018/GA/46784

- **ECDL (Full Standard Certificate)** July 2015– License IT 2102025

FOREIGN EXPERIENCE

April 2018 - June 2018

Visiting Scientist at "The Danish Cancer Society" (KræftensBekæmpelse) - Copenhagen-Denmark

PUBLICATIONS

1) In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma. Int J Mol Sci. 2020 Mar; 21(6): 1930. Published online 2020 Mar 12. doi:10.3390/ijms21061930

2) Single cell analysis to dissect molecular heterogeneity and disease evolution in metastatic melanoma. Cell Death & Disease. (accepted) Review. (IF=5.959)

3) ErbB3 phosphorylation as central event in adaptive resistance to BRAF/MEK inhibitors in metastatic melanoma: early detection in CTCs during therapy and insights into regulation by autocrine Neuregulin. Cancers. (first author) Cancers (Basel). 2019 Sep 25;11(10). pii: E1425. doi: 10.3390/cancers11101425. (IF=6.162)

4) Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma. Cell Death & Differentiation. 2018 Sep 25. doi:10.1038/s41418-018-0205-5. (IF=8.086). (co-first

author)

5) MicroRNAs in melanoma development and resistance to target therapy. Oncotarget. 2017 Jan 19. doi: 10.18632/oncotarget.14763. [Epubahead of print] Review.(IF=NA)

CONGRESSES AND MEETING

CONGRESSO NAZIONALE IMI 2019, Bologna, 10-12 Nov 2019 (POSTER)

EACR-ESMO JOINT CONFERENCE ON LIQUID BIOPSIES 2019, Bergamo, 15-17 May 2019 (POSTER)

EORTC-PAMM 2019, Verona, 7-9 Feb 2019 (POSTER)

CONGRESSO NAZIONALE IMI 2018, Bari, 4-6 Nov 2018 (POSTER AND ORAL COMUNICATION)

MELANOMA BRIDGE 2017, Napoli 30 Nov – 2 Dic (POSTER)

SIBBM 2016, Napoli, 16-18 Jun 2016 (POSTER)

DRIVING LICENSE

Category B

The undersigned Ciro Francesco Ruggiero, aware that false declarations entail the application of the penalties provided for by art. 76 of the Presidential Decree 445/2000, declares that the information reported in the following curriculum vitae is true.

Use of my personal data is authorized according to in force legislation.

Rome, 26/06/2020

CiroFrancescoRuggiero